Explore more publications!

STEM Times of Connecticut: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on STEM Times of Connecticut.

Press releases published on February 27, 2026

A Practical Guide to Courageous Innovation and Transformational Leadership
VLink Earns Great Place To Work® Certification for the Third Consecutive Year
Teleworks Announces Strategic Partnership with Verizon to Deliver Business Fiber & 5G Internet Across Connecticut
IGEL Continues Executive Leadership Expansion with Appointment of Ash Chowdappa as Chief Product & Development Officer
FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
OpGen, Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
Ramsey Theory Group CEO Dan Herbatschek Announces Ashutosh Sharma Appointed to Head of Engineering
IGEL Continues Executive Leadership Expansion with Appointment of Ash Chowdappa as Chief Product & Development Officer
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
Microchip Technology to Present at the Raymond James Institutional Investors Conference
Microchip Technology to Present at the Morgan Stanley Technology, Media & Telecom Conference
PrimeEnergy Resources Corporation Announces Borrowing Base Reaffirmation and Pricing Reduction Under Credit Facility
Draganfly Announces Closing of US$50.0 Million Registered Direct Offering
Aardvark Therapeutics Announces Voluntary Pause of Phase 3 HERO Trial in Prader-Willi Syndrome
NurExone to Showcase Its Regenerative Medicine Platform at NANO.IL.2026 and Advanced Therapies Congress in March 2026 and Provides Corporate Update
Arcutis Management to Present at TD Cowen’s 46th Annual Health Care Conference
Enrollment Opens for K12-Powered Virtual Public Schools Serving Students Across Ohio
Enrollment Opens for K12-Powered Virtual Public Schools Serving Students Across Missouri
Excellergy Presents New Data at 2026 AAAAI Annual Meeting Demonstrating Rapid and Sustained Allergic Effector Cell Control and Announces First Subjects Dosed in Phase 1 DISARM Trial
Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at…

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions